CClinicalTrials.gg
Status unknownNCT02828878Updated Nov 26, 2019

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

A Phase 1/2 interventional study of Allogeneic MPBC transplantation from matched related donor in Hematological Malignancies, sponsored by Cellect Biotechnology. Status unknown at 2 sites in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-26.

Sponsored by Cellect Biotechnology · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Interventional, open label, Phase I/II, Safety and Proof-of-Concept Study, with a follow up period of 180 days after the transplantation of ApoGraft.

Read the detailed description

ApoGraft product is a mobilized peripheral blood cell product of a matched Related donor, collected via apheresis, which is exposed to the apoptotic mediator Fas Ligand (CD95L) prior to transplantation (Ex Vivo).

The study is designed to address the aspects of engraftment and Prevention of Acute Graft versus Host Disease (aGvHD) rate and/or severity in 12 Patients

STUDY DESIGN:

This is a phase 1/2, open-label, proof-of-concept, staggered 4-cohort clinical study. Each cohort will include 3 patients with hemato-oncology disorders eligible for allogeneic HLA-matched HSCT. Patients in all cohorts will undergo similar study procedures and evaluation. The cohorts will differ from each other in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplantation and HSCT, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3 and 100 ng/ml APO010 in Cohort 4. APO010 is washed-out as part of the ApoGraft process and only trace amounts of APO010 are present in the final ApoGraft product

The study consists of a screening phase (subject and donor clinical assessment and screening tests), transplantation of ApoGraft, and a follow-up period of 180 days during and after hospitalization.

The study will progress from one cohort to the next based on an independent data safety monitoring board (DSMB) review and analysis of safety data

02

Conditions studied

  • Hematological Malignancies

Keywords

  • Apoptosis
  • FAS Ligand
  • Bone marrow transplantation
  • GvHD
  • Stem cells
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Recipient/patient main inclusion criteria:

  1. Adult male or female subjects, 18-70 years of age.
  2. Subjects are eligible for allogeneic HLA-matched related HSCT for any hematological malignancies for which transplantation is appropriate with corresponding related donor. One of the following hemato-oncology disorders diagnosis is required:

    • Acute myelogenous leukemia (AML) and Acute lymphoblastic leukemia (ALL) in 1st or subsequent complete remission (CR)
    • Non-Hodgkin's disease (NHD) in CR by CT or PET/CT
    • Hodgkin's disease (HD) in 1st or subsequent CR by CT or PET/CT
    • Intermediate, High or Very High Risk Myelodysplastic syndrome (MDS) (IPSS-R criteria)
  3. The donor and recipient must have full match at the HLA A, B, C, DR and DQ loci.
  4. ECOG performance status score 0-1 at time of the screening visit.
  5. Subjects must have adequate organ function as defined in the study protocol
  6. Signed written informed consent to participate in the study.
  7. If female of childbearing potential, agree to use an acceptable method of birth control or be surgically sterile, and have a negative pregnancy test.

Donor main inclusion criteria:

  1. Adult male or female subjects, 18-65 years of age.
  2. Donor criteria according to standard WMDA criteria for donor selection. 3 Must have full match at the HLA A, B, C, DR and DQ loci with the recipient.
  1. Signed written informed consent

Recipient/patient main exclusion criteria:

  1. Use of non-myeloabletive conditioning.
  2. Uncontrolled infections including sepsis, pneumonia with hypoxemia, persistent bacteremia, or meningitis within two weeks of the screening visit.
  3. Current known acute or chronic infection with HBV or HCV.
  4. Known human immunodeficiency virus (HIV) infection or AIDS.
  5. Subjects with severe or symptomatic restrictive or obstructive lung disease or respiratory failure requiring ventilator support.
  6. Subjects with other concurrent severe and/or uncontrolled medical condition, which could compromise participation in the study (i.e. active infection, uncontrolled diabetes, uncontrolled hypertension, congestive cardiac failure, unstable angina, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months and chronic liver or renal disease.
  7. Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder or any chronic condition susceptible, in the opinion of the investigator, of interfering with the conduct of the study.
  8. Organ allograft or previous history of allogeneic stem cell transplantation.
  9. Pregnancy or lactation.

Donor main exclusion criteria:

  1. HIV, HBV or HCV positive subjects.
  2. Pregnant or lactating women.
  3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    ApoGraft

    ApoGraft is a mobilized peripheral blood cell (MPBC) product derived from peripheral blood. There will be 4 cohorts, each differ in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplant, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3, and 100 ng/ml APO010 in Cohort 4

    Biological: Allogeneic MPBC transplantation from matched related donor

Interventions

  • BiologicalAllogeneic MPBC transplantation from matched related donor
05

What researchers measure

Primary outcomes

  1. Overall incidence, frequency and severity of adverse events (AEs) potentially related to the product during the study

    Time frame: 180 days from transplantation

Secondary outcomes

  1. Determination of the optimal dose of FasL concentration that facilitates the biological activity of the ApoGraft process

    Time frame: 180 days from transplantation

  2. Time of neutrophils engraftment determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3

    Time frame: 28 days from transplantation

  3. Rate of neutrophils engraftment determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3

    Time frame: 28 days from transplantation

  4. Time of platelets engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days

    Time frame: 180 days from transplantation

  5. Rate of platelets engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days

    Time frame: 180 days from transplantation

  6. Incidence to development of aGvHD

    Time frame: 180 days from transplantation

  7. Time to development of aGvHD

    Time frame: 180 days from transplantation

  8. Non-relapse mortality

    Time frame: 180 days from transplantation

  9. Proportion of patients with disease relapse

    Time frame: 180 days from transplantation

  10. Proportion of patients with progression free and overall survival

    Time frame: 180 days from transplantation

06

Study locations

2 of 2 sites recruiting
  • Rambam Health Care Campus
    Haifa, Israel
    • Tsila Zuckerman, MD · Principal investigator
    Recruiting
  • Hadassah Medical Center, Ein Kerem, Jerusalem
    Jerusalem, Israel
    • Polina Stephanski, MD · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT02828878
Lead sponsor
Cellect Biotechnology
Responsible party
Sponsor
First posted
Jul 12, 2016
Start date
Jan 2017
Primary completion
Jul 2020 (estimated)
Completion
Jul 2020 (estimated)
Last update
Nov 26, 2019

Study contacts

Shai Yarkoni, MD
Contact
shai@cellect.co
972-9-9741444
Tsila Zuckerman, MD
principal investigator · Rambam Hospital, Haifa, Israel

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion